The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
IMPRESS-Norway: Improving public cancer care by implementing precision cancer medicine in Norway.
 
Aslaug Helland
Research Funding - AstraZeneca (Inst); Bristol Myers Squibb (Inst); Illumina (Inst); InCyte (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Roche (Inst); Ultimovacs (Inst)
 
Sigbjørn Smeland
Research Funding - AstraZeneca (Inst); Illumina (Inst); Incyte (Inst); Lilly O. (Inst); Merck (Inst); Novartis (Inst); Roche (Inst)
 
Hege Russnes
Research Funding - AstraZeneca (Inst); Illumina (Inst); Incyte (Inst); Merck (Inst); Novartis (Inst); Novartis (Inst); Roche (Inst)
 
Sigmund Brabrand
Honoraria - Astellas Pharma
Research Funding - AstraZeneca (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Roche (Inst)
 
Katarina Puco
Stock and Other Ownership Interests - Ultimovacs (I)
Honoraria - Astellas Pharma; Bayer Norway; Bayer Norway; Bristol-Myers Squibb Norway; Ipsen; Janssen-Cilaq; Pfizer
Consulting or Advisory Role - Bayer Norway; MSD; Pfizer
Research Funding - AstraZeneca (Inst); Illumina (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Roche (Inst)
 
Pitt Niehusmann
Research Funding - AstraZeneca (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Roche Pharma AG (Inst)
 
Marte Grønlie Cameron
Research Funding - AstraZeneca (Inst); Illumina (Inst); Incyte (Inst); Lilly O. (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst)
 
Egil Blix
Research Funding - AstraZeneca (Inst); Illumina (Inst); Incyte (Inst); Lilly O. (Inst); Merck (Inst); Novartis (Inst); Roche (Inst)
 
Ase Haug
Research Funding - AstraZeneca (Inst); Illumina Radiopharmaceuticals (Inst); Incyte (Inst); Lilly O. (Inst); Merck (Inst); Novartis (Inst); Roche (Inst)
 
Irja Alida Oppdal
Research Funding - AstraZeneca (Inst); Illumina (Inst); Incyte (Inst); Lilly O. (Inst); Merck (Inst); Novartis (Inst); Roche (Inst)
 
Daniel Heinrich
Stock and Other Ownership Interests - Ultimovacs
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Ferring; Ipsen; Janssen; Merck, Sharp & Dohme (MSD); Pfizer
Consulting or Advisory Role - Bayer; Eisai
Research Funding - AstraZeneca (Inst); Eisai (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - IPSEN
 
Sebastian Meltzer
Research Funding - AstraZeneca (Inst); BMS Norway (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Roche (Inst)
 
Åsmund Flobak
Honoraria - Bayer; Novartis; Pfizer
Consulting or Advisory Role - Novartis
Speakers' Bureau - Bayer; Pfizer
Research Funding - AstraZeneca (Inst); InCyte (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - Computational algorithms for drug response prediction, patent pending
 
Eli Sihn Steinskog
Research Funding - AstraZeneca (Inst); Illumina (Inst); Incyte (Inst); Lilly O. (Inst); Merck (Inst); Novartis (Inst); Roche (Inst)
 
Cecilie Fredvik Torkildsen
Research Funding - AstraZeneca (Inst); Illumina (Inst); Incyte (Inst); Lilly O. (Inst); Merck (Inst); Novartis (Inst); Roche (Inst)
 
Gro Live Fagereng
Research Funding - AstraZeneca (Inst); Illumina (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Roche
 
Astrid Dalhaug
Research Funding - AstraZeneca (Inst); Illumina (Inst); Incyte (Inst); Lilly O. (Inst); Merck (Inst); Novartis (Inst); Roche (Inst)
 
Geir Olav Hjortland
Honoraria - Bristol-Myers Squibb Norway (Inst); MSD (Inst)
Consulting or Advisory Role - Bristol-Myers Squibb Norway (Inst)
Research Funding - Bristol-Myers Squibb Norway (Inst)
 
Line Bjørge
Consulting or Advisory Role - GlaxoSmithKline
Speakers' Bureau - MSD
Research Funding - AstraZeneca (Inst); Incyte (Inst); Lilly O. (Inst); Merck (Inst); Novartis (Inst); Roche (Inst)
Other Relationship - AstraZeneca
 
Kjetil Tasken
Stock and Other Ownership Interests - Ledidi; Serca Pharmaceuticals
Consulting or Advisory Role - Serca Pharmaceuticals
Research Funding - AstraZeneca (Inst); Illumina (Inst); Incyte (Inst); Lilly (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Stock and Stock options, and royalty agreement through Oslo University Hospital / University of Oslo Tech Transfer Office Inven2 AS.
Travel, Accommodations, Expenses - Roche